Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium Voltage-Gated Channel Subfamily H Member 2 (hERG), also known as Kv11.1, is a voltage-dependent potassium channel crucial for cardiac action potential repolarization. Encoded by the KCNH2 gene, hERG is a tetramer forming a pore in the plasma membrane. Its unique structure, including a central cavity with hydrophobic pockets, makes it susceptible to blockade by various drugs, leading to potential cardiac arrhythmias like Long QT syndrome and Torsade de pointes. hERG contains cytoplasmic domains such as the PAS domain in the N-terminus and a cyclic nucleotide binding domain (cNBD) in the C-terminus.
hERG channel blockade
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium Voltage-Gated Channel Subfamily H Member 2 (hERG).